Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination involves five chemotherapy drugs: **etoposide**, **methotrexate**, **lomustine**, **cyclophosphamide**, and **thiotepa**. - **Etoposide** works by inhibiting topoisomerase II, an enzyme that allows cancer cells to grow and divide. It causes DNA double-strand breaks, leading to cell apoptosis[5]. - **Methotrexate** inhibits dihydrofolate reductase, essential for DNA synthesis, thereby preventing cancer cells from dividing[5]. - **Lomustine** is an alkylating agent that binds to DNA, causing cross-linking and preventing DNA replication[3]. - **Cyclophosphamide** is an alkylating agent that damages DNA through cross-linking, leading to cell death[3]. - **Thiotepa** is also an alkylating agent, similar to cyclophosphamide and lomustine, used to treat various cancers and in bone marrow transplantation conditioning[6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on etoposide + methotrexate + lomustine + cyclophosphamide + thiotepa.